6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05109364 (ClinicalTrials.gov) | November 23, 2021 | 13/10/2021 | Terazosin and Parkinson's Disease Extension Study | The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study | Symptomatic Parkinson Disease;REM Sleep Behavior Disorder;Pre-motor Parkinson's Disease | Drug: Terazosin therapy | Cedars-Sinai Medical Center | NULL | Not yet recruiting | 25 Years | 85 Years | All | 15 | Phase 2 | NULL |